SAFIR ABC-10 is a Phase 3, international (UK, France, Belgium) multicentre, randomised, trial to evaluate whether the introduction of molecular targeted therapy as maintenance treatment after 4 cycles of standard-of-care first-line systemic therapy* is better than the continuation of standard-of-care first-line systemic therapy in the treatment of patients with Advanced Biliary Cancer (ABC; cholangiocarcinoma; bile duct cancer). 

The trial is composed of two phases: 

1 An initial screening phase to identify suitable patients

2 A randomised comparative trial

*Current standard-of-care first-line systemic therapy is durvalumab plus gemcitabine and cisplatin. For more information on this, see:

The study is now open in one site in the UK, with more to follow.

Below is an overview showing how the trial will work, the actionable targets and the therapies that may be used.  

Back to previous page